ABIONYX Pharma is in advanced discussions with the IHU SEPSIS

ABIONYX Pharma, a biopharmaceutical company specializing in sepsis and critical care, announces that it is in advanced discussions with the IHU SEPSIS. This center is recognized worldwide for its work on sepsis. The objective is to develop a long-term scientific and strategic collaboration.

The IHU SEPSIS, based in Paris, is a center of excellence bringing together 275 researchers and 94 clinicians. It has a strong international presence, enabling large-scale validation of therapeutic innovations. This alliance aims to create an integrated global platform dedicated to the treatment of sepsis.

These discussions follow the publication of research on the apolipoprotein apoA-I, reinforcing interest in ABIONYX as a key player in the treatment of sepsis. An announcement regarding the precise terms of the partnership may follow soon.